AVENUE THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
ATXI$0.42-50.7%Stored close · as of Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Changes in Stockholders’** Equity**
(In thousands, except share amounts)
| Class A Preferred Stock · Common Shares · Additional paid-in · Accumulated · Non-Controlling · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | Interests | equity | |
| Balance at December 31, 2023 | 250,000 | — | 341,324 | 3 | 92,507 | (90,928) | (928) | 654 |
| Share based compensation | — | — | 283 | — | 1,236 | — | — | 1,236 |
| Issuance of common stock to Fortress | — | — | 179,098 | — | 827 | — | — | 827 |
| Common shares issuable - Founders Agreement | — | — | — | — | (167) | — | — | (167) |
| Loss on settlement of common stock warrant liabilities | — | — | — | — | 1,159 | — | — | 1,159 |
| Exercise of warrants | — | — | 910,218 | 1 | 9,420 | — | — | 9,421 |
| Warrant inducement offering costs | — | — | — | — | (1,207) | — | — | (1,207) |
| Issuance of common stock, net of offering costs under open market sales agreement (ATM) | — | — | 591,205 | — | 1,623 | — | — | 1,623 |
| Reverse split (1-for-75) | — | — | 86,542 | (4) | 4 | — | — | — |
| Issuance of subsidiaries' common stock for license expenses | — | — | — | — | 6 | — | — | 6 |
| Non-controlling interest in subsidiaries | — | — | — | — | (31) | — | 31 | — |
| Net loss attributable to non-controlling interest | — | — | — | — | — | — | (44) | (44) |
| Net loss attributable to common stockholders | — | — | — | — | — | (11,652) | — | (11,652) |
| Balance at December 31, 2024 | $250,000 | $— | $2,108,670 | $— | $105,377 | $(102,580) | $(941) | $1,856 |
| Share based compensation | — | — | 239 | — | 665 | — | — | 665 |
| Issuance of common stock to Fortress | — | — | 135,659 | — | 55 | — | — | 55 |
| Common shares issuable - Founders Agreement | — | — | — | — | 76 | — | — | 76 |
| Issuance of common stock, net of offering costs under open market sales agreement (ATM) | — | — | 938,990 | — | 2,094 | — | — | 2,094 |
| Shares receivable from AnnJi | — | — | — | — | (4) | — | — | (4) |
| Forgiveness of subsidiary debt and deconsolidation | — | — | — | — | (942) | — | 979 | 37 |
| Net loss attributable to non-controlling interest | — | — | — | — | — | — | (38) | (38) |
| Net loss attributable to common stockholders | — | — | — | — | — | (2,909) | — | (2,909) |
| Balance at December 31, 2025 | 250,000 | $— | 3,183,558 | $— | $107,321 | $(105,489) | $— | $1,832 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.